Expressing support for the designation of the month of May 2026 as "Progressive Supranuclear Palsy and Corticobasal Degeneration Awareness Month".

119th Congress Introduced by Don Bacon and 23 co-sponsors

The bill designates May 2026 as PSP and CBD Awareness Month to boost public understanding, research, diagnosis, and support for these neurodegenerative diseases.

Submitted in House

Bill Overview

Bill: H.R. 1318

Session: 119th Congress, 2nd Session

Type: House resolution

Title: Expressing support for the designation of May 2026 as “Progressive Supranuclear Palsy and Corticobasal Degeneration Awareness Month”

Sponsor: Suhas Subramanyam (with multiple cosponsors)

Status: Referred to the House Committee on Energy and Commerce (as of May 21, 2026)

Purpose and Intent

The resolution expresses support for designating May 2026 as Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD) Awareness Month.

It aims to raise awareness about PSP and CBD, two rare adult-onset neurodegenerative diseases, and to recognize the impact on patients, families, and caregivers.

The measure emphasizes the need for increased research, diagnosis, treatment, support services, and education related to PSP and CBD.

Key Provisions

Formal designation: Supports designation of May 2026 as PSP and CBD Awareness Month.

Awareness and goals: Endorses the goals and ideals of awareness month, including public awareness, education, and advocacy.

Research and treatment: Calls for continued or increased research on diagnosis, prevention, treatments, and potential cures for PSP and CBD.

Recognition of community: Acknowledges the strength and resilience of individuals affected by PSP and CBD, as well as families, caregivers, healthcare professionals, researchers, and related organizations.

Support for stakeholders: Commends the broader community involved in improving quality of life and outcomes for those with PSP and CBD.

Who Would Be Affected

Patients diagnosed with PSP or CBD and their families and caregivers.

Healthcare professionals specializing in neurology and neurodegenerative diseases.

Researchers and organizations conducting studies and advocacy related to PSP and CBD.

The broader medical and public health community, through heightened awareness and potential increases in funding or focus on these conditions.

Procedural and Timeline Details

Introduction date: May 21, 2026.

Referral: Committee on Energy and Commerce.

No explicit funding authorization or statutory changes are contained in the resolution; it functions as a symbolic and educational measure to promote awareness and support.

As a resolution, it would not create new programs or obligations; rather, it would recognize and encourage efforts related to PSP and CBD awareness during May 2026.

Notable Context

Estimated prevalence (as described in the resolution): approximately 30,000 Americans living with PSP and about 2,000 living with CBD.

Diseases described as distinct from other neurological conditions (e.g., Parkinson’s disease, frontotemporal dementia) with unique trajectories and care needs.

Emphasizes lack of disease-modifying treatments for PSP and CBD and the need for better diagnosis, access to neurology care, and research into environmental and genetic factors.

If you would like, I can add a brief comparison to related neurological awareness campaigns or provide a glossary of PSP and CBD terms for readers new to these conditions.